BridgeBio Pharma, Inc.
BBIONASDAQHealthcare● Active
$67.90
+$0.29(+0.43%)
Market Cap$13.3B
P/E Ratio—
52W High$84.94
52W Low$37.69
BridgeBio Pharma, Inc. (BBIO) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
BBIO · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 7, 2026EPS Actual
-$0.84
Est. -$0.68 · -23.8%
Revenue
$0.19B
Est. $0.18B · +9.2%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 7, 2026
After Market Close
▼ Miss EPS▲ Beat Revenue
BBIO reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Rev. $0.84B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
Rev. Est.$0.84B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 4, 2026 | -$0.63 | — | — | — | $0.22B | — |
| ▼ Q2 FY2026 | May 7, 2026 | -$0.68 | -$0.84 | -23.8% | $0.19B | $0.18B | +9.2% |
| ▼ Q1 FY2026 | Feb 24, 2026 | -$0.71 | -$1.00 | -40.2% | $0.15B | $0.15B | +5.0% |
| ▼ Q4 FY2025 | Oct 29, 2025 | -$0.88 | -$0.95 | -8.0% | $0.12B | $0.15B | -18.5% |
| ▼ Q3 FY2025 | Aug 5, 2025 | -$0.83 | -$0.95 | -14.5% | $0.11B | $0.11B | +2.3% |
| ▲ Q2 FY2025 | Apr 29, 2025 | -$1.00 | -$0.88 | +12.0% | $0.12B | $0.07B | +70.5% |
| ▼ Q1 FY2025 | Feb 20, 2025 | -$1.09 | -$1.31 | -20.2% | $0.01B | $0.00B | +45.6% |
| ▲ Q4 FY2024 | Nov 12, 2024 | -$1.03 | -$0.86 | +16.5% | $0.00B | $0.07B | -95.9% |
Q3 FY2026
Aug 4, 2026
EPS Actual
—
EPS Est.
-$0.63
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 7, 2026Miss
EPS Actual
-$0.84
EPS Est.
-$0.68
EPS Surpr.
-23.8%
Revenue
$0.19B
Q1 FY2026
Feb 24, 2026Miss
EPS Actual
-$1.00
EPS Est.
-$0.71
EPS Surpr.
-40.2%
Revenue
$0.15B
Q4 FY2025
Oct 29, 2025Miss
EPS Actual
-$0.95
EPS Est.
-$0.88
EPS Surpr.
-8.0%
Revenue
$0.12B
Q3 FY2025
Aug 5, 2025Miss
EPS Actual
-$0.95
EPS Est.
-$0.83
EPS Surpr.
-14.5%
Revenue
$0.11B
Q2 FY2025
Apr 29, 2025Beat
EPS Actual
-$0.88
EPS Est.
-$1.00
EPS Surpr.
+12.0%
Revenue
$0.12B
Q1 FY2025
Feb 20, 2025Miss
EPS Actual
-$1.31
EPS Est.
-$1.09
EPS Surpr.
-20.2%
Revenue
$0.01B
Q4 FY2024
Nov 12, 2024Beat
EPS Actual
-$0.86
EPS Est.
-$1.03
EPS Surpr.
+16.5%
Revenue
$0.00B
Analyst Estimates
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2029 | $2.06 | $2.28 | $2.84 | 4 |
| Q3 FY2029 | $1.89 | $2.10 | $2.61 | 3 |
| Q2 FY2029 | $1.75 | $1.93 | $2.41 | 3 |
| Q1 FY2029 | $1.60 | $1.77 | $2.21 | 4 |
| Q4 FY2028 | $1.05 | $1.16 | $1.44 | 3 |
| Q3 FY2028 | $0.88 | $0.97 | $1.21 | 3 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2029 | $0.9B | $0.9B | $1.1B | 11 |
| Q3 FY2029 | $0.8B | $0.9B | $1.0B | 10 |
| Q2 FY2029 | $0.7B | $0.8B | $0.9B | 10 |
| Q1 FY2029 | $0.7B | $0.7B | $0.9B | 11 |
| Q4 FY2028 | $0.6B | $0.7B | $0.8B | 6 |
| Q3 FY2028 | $0.6B | $0.6B | $0.7B | 5 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 7, 2026 | -23.8% | $68.09 | $67.45 | -0.94% |
| ▼ Q1 FY2026 | Feb 24, 2026 | -40.2% | $67.91 | $68.31 | +0.59% |
| ▼ Q4 FY2025 | Oct 29, 2025 | -8.0% | $64.50 | $66.62 | +3.29% |
| ▼ Q3 FY2025 | Aug 5, 2025 | -14.5% | $47.75 | $49.21 | +3.06% |
| ▲ Q2 FY2025 | Apr 29, 2025 | +12.0% | $35.89 | $36.42 | +1.48% |
| ▼ Q1 FY2025 | Feb 20, 2025 | -20.2% | $36.29 | $36.81 | +1.43% |
| ▲ Q4 FY2024 | Nov 12, 2024 | +16.5% | $26.12 | $24.62 | -5.74% |
| ▲ Q3 FY2024 | Aug 1, 2024 | +6.4% | $25.95 | $26.18 | +0.89% |
Q2 FY2026-0.94%
Report Date
May 7, 2026
EPS Beat/Miss
-23.8%
Price Before
$68.09
Price After
$67.45
Q1 FY2026+0.59%
Report Date
Feb 24, 2026
EPS Beat/Miss
-40.2%
Price Before
$67.91
Price After
$68.31
Q4 FY2025+3.29%
Report Date
Oct 29, 2025
EPS Beat/Miss
-8.0%
Price Before
$64.50
Price After
$66.62
Q3 FY2025+3.06%
Report Date
Aug 5, 2025
EPS Beat/Miss
-14.5%
Price Before
$47.75
Price After
$49.21
Q2 FY2025+1.48%
Report Date
Apr 29, 2025
EPS Beat/Miss
+12.0%
Price Before
$35.89
Price After
$36.42
Q1 FY2025+1.43%
Report Date
Feb 20, 2025
EPS Beat/Miss
-20.2%
Price Before
$36.29
Price After
$36.81
Q4 FY2024-5.74%
Report Date
Nov 12, 2024
EPS Beat/Miss
+16.5%
Price Before
$26.12
Price After
$24.62
Q3 FY2024+0.89%
Report Date
Aug 1, 2024
EPS Beat/Miss
+6.4%
Price Before
$25.95
Price After
$26.18
Avg Beat Reaction-1.12%
Avg Miss Reaction+1.49%
Beat Rate3 / 8 quarters
Largest Move-5.74% (Q4 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: BBIO ends December
BridgeBio Pharma, Inc. (BBIO) most recently reported earnings on May 7, 2026 for Q2 FY2026, posting EPS of $-0.84 — missing the analyst consensus of $-0.68 by -23.8%. The next BBIO earnings date is expected around September 1, 2026.
Each quarter, investors track BBIO earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. BBIO revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
BBIO's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
BBIO earnings · 5 questionsBridgeBio Pharma, Inc.'s next earnings report is expected around September 1, 2026. BBIO typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; BBIO historically reports after market close (AMC).
BBIO earnings datewhen is BBIO earningsBBIO next earnings datewhen does BBIO report earningsBBIO earnings calendar
▸ Source: FMP · BridgeBio Pharma, Inc. SEC filings · US GAAP · BridgeBio Pharma, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026